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ABSTRACT
Objectives: To estimate the cost-effectiveness of five face-
to-face smoking cessation interventions (i.e., minimal
counseling by a general practitioner (GP) with, or without
nicotine replacement therapy (NRT), intensive counseling
with NRT, or bupropion, and telephone counseling) in
terms of costs per quitter, costs per life-year gained, and
costs per quality-adjusted life-year (QALY) gained.
Methods: Scenarios on increased implementation of
smoking cessation interventions were compared with
current practice in The Netherlands. One of the five
interventions was implemented for a period of 1, 10, or
75 years reaching 25% of the smokers each year. A
dynamic population model, the RIVM chronic disease
model, was used to project future gains in life-years and
QALYs, and savings of health-care costs from a decrease
in the incidence of 11 smoking-related diseases over a
time horizon of 75 years. This model allows the repetitive
application of increased cessation rates to a population
with a changing demographic and risk factor mix.
Sensitivity analyses were performed for variations in
costs, effects, time horizon, program size, and discount
rates.
Results: Compared with current practice, minimal GP
counseling was a dominant intervention, generating both
gains in life-years and QALYs and savings that were
higher than intervention costs. For the other interven-
tions, incremental costs per QALY gained ranged from
about 1100€ for telephone counseling to 4900€ for inten-
sive counseling with nicotine patches or gum for imple-
mentation periods of 75 years.
Conclusions: All five smoking cessation interventions
were cost-effective compared with current practice, and
minimal GP counseling was even cost-saving.
Keywords: bupropion, cost-effectiveness, counseling, dyn-
amic modeling, nicotine replacement therapy, smoking
cessation.
Introduction
Smoking is a leading cause of preventable morbidity
and mortality. It incurs high costs to the society. The
World Bank estimated that 6% to 15% of total
health-care costs were attributable to smoking in
high-income countries [1].
For many smokers, it is hard to quit smoking on
will power alone. Only 3% to 7% of the smokers
who attempt to stop smoking on will power are still
abstinent after 1 year [2,3]. A wide range of policy
measures and therapies is available to increase this
rate, varying from price increases by taxation,
media campaigns, or self-help manuals, to intensive
individual counseling combined with pharmaceuti-
cal therapies. For smoking cessation interventions
administered by medical professionals, the percent-
age of sustained quitters ranges from 7% to 24%
[4–6].
Reviews of the cost-effectiveness of smoking
cessation interventions [7–9] show that the costs of
these interventions are relatively low compared
with the resulting gains in terms of avoided mortal-
ity, morbidity, and costs of care for smoking-related
diseases. Costs per life-year gained varied between
about 200€ and 10,000€ when converted into
Dutch currency using purchasing power parity rates
[10] and updated to the year 2000 with consumer
price indices. The majority of studies reported cost-
effectiveness ratios around 2500€ per life-year
gained [7–9,11–23]. These figures should be inter-
preted very carefully, because the transfer of results
from economic studies between countries is diffi-
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cult. None of these studies included savings in costs
of care from avoided smoking-related morbidity or
took account of the fact that former smokers may
restart smoking after more than 12 months of con-
tinuous abstinence.
The present study aims to examine cost-
effectiveness for a specific set of smoking cessation
interventions, i.e., face-to-face smoking cessation
interventions administered by professionals with
proven effectiveness in terms of cessation rates. Five
different cessation interventions (i.e., minimal coun-
seling by a general practitioner (GP) with, or with-
out nicotine replacement therapy (NRT), intensive
counseling with NRT, or bupropion, and telephone
counseling) were compared with current practice to
report cost-effectiveness ratios for different imple-
mentation periods. The selection of interventions
was driven by the fact that the study was initiated
by the Dutch Public–Private Partnership to reduce
tobacco dependence to support them in developing
Dutch smoking cessation guidelines for healthcare
professionals. Therefore, we selected interventions
that are currently applied in The Netherlands. A
computer simulation model was used to project the
future gains in life-years, QALYs, and the savings in
health-care costs that result from a decrease in the
incidence of smoking-related diseases, over a time
horizon of 75 years. The strength of the model is
that it is dynamic, allowing us to apply increased
cessation rates on a repetitive basis to a population
whose mix of age, sex, and smoking prevalence
changes annually.
Methods
Smoking Cessation Interventions
This study focused on face-to-face smoking cessa-
tion interventions, administered by medical profes-
sionals or educated smoking cessation counselors.
They had to have a proven effectiveness in terms of
cessation rates from international meta-analyses [4–
7] or Dutch trial data [24,25] and had to be cur-
rently available in The Netherlands. Based on these
criteria, the following smoking cessation interven-
tions were analyzed:
1. MC: Minimal counseling by a GP and/or a GP-
assistant in one or two consultations with a
total length of 12 minutes [24,26].
2. MC + NRT: Minimal GP counseling in combi-
nation with nicotine patches or gum (NRT) for
a period of 8 weeks [5].
3. IC + NRT: Intensive counseling by a trained
counselor in combination with NRT for a
period of 12 weeks. We assumed the counseling
would be performed by a trained lung nurse
for a total of 90 minutes plus a 2-minute stop
advice from a lung physician [5,27].
4. IC + Bupr: Intensive counseling by a trained
lung nurse, plus a 2-minute stop advice by a
lung specialist in combination with bupropion
for a period of 9 weeks [4,27].
5. TC: Telephone counseling as currently provided
by the Dutch Foundation on Smoking and
Health (STIVORO), consisting of one intake
call of 30 minutes and 6 follow-up calls, each
lasting up to 15 minutes, based on a (compu-
terized) questionnaire completed by the poten-
tial quitters [6,25,28].
The impact of different intervention scenarios
on the future costs and the gain in life-years and
QALYs were studied. All scenarios were compared
with current practice. The intervention scenarios
assumed an increased implementation of one of the
five smoking cessation interventions for a period of
1, 10, or 75 years. The interventions were assumed
to reach 25% of the smokers each year. This per-
centage was based on the percentage of smokers in
the preparation state (ready to make a serious
attempt at quitting), which has been estimated at
26% [29,30].
Current Practice
Current practice was defined as the mix of all cur-
rent initiatives to stop smoking, including the
above-mentioned five interventions, and will power
alone. The estimated current use of the five selected
interventions in The Netherlands is shown in
Table 1. For example, 0.36% for MC means that
currently 0.36 per 100 smokers in The Netherlands
receive minimal counseling by the GP. Annually,
about 1.3% of smokers used one of the five selected
interventions.
In the chronic disease model, prevalence rates of
current and former smokers among the Dutch pop-
ulation by sex and 5-year age class were based on
yearly population monitoring studies of STIVORO
between 1997 and 2000 [28,31–34]. Start, cessa-
tion, and restart rates in the current practice sce-
nario were estimated for each 5-year age and sex
class from 10 to 14 years of age to the age class
more than 85 years. These estimates were based on
STIVORO data (1998–1999) [32,33] and three
Dutch cohort studies [35–37]. Men start smoking
between 10 and 29 years of age and women
between 10 and 24 years of age. Start rates in other
age categories were zero. The cessation rates
approximate 12-month continuous abstinence
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rates. They increased with age from 0.007 in
women aged 10 to 14 years to 0.051 in women aged
70 years and older, and from 0.007 in men aged 10
to 14 years to 0.049 in men aged 60 years and older.
The average smoking cessation rate of the current
practice scenario across all age groups and sexes
was 0.034 or 3.4%. Restart rates in the model
reflect former smokers starting to smoke again after
having been abstinent in the previous year. Restart
rates rise with age to a maximum of 0.099 for men
aged between 40 and 44 years and a maximum of
0.114 for women aged between 40 and 44 years,
after which they fall by age. By assumption, no
relapse exists among men older than 74 years and
women older than 79 years. The average restart rate
was 0.042.
Intervention Scenarios
Effectiveness in terms of cessation rates was
expressed as 12 months prolonged abstinence rates.
These rates were obtained from randomized con-
trolled trials as included in Cochrane meta-analyses
[4–6] and from Dutch trials [24,25], which were
summarized in a review by Willemsen et al. [38]. In
calculating these rates, participants with missing
follow-up data were treated as smokers. Table 2
lists these abstinence rates for the different smoking
cessation interventions. These rates were not age-
specific. To compute age- and sex-specific cessation
rates for the intervention scenarios, for each inter-
vention, the ratio of its abstinence rate and the aver-
age current practice cessation rate of 3.4% were
calculated. For example, the ratio of MC and cur-
rent practice is 7.9/3.4, which is about 2.3. Then,
the age- and sex-specific current practice cessation
rates were multiplied by this ratio. During the
increased implementation period of either 1, 10, or
75 years, 25% of all smokers were given the smok-
ing cessation intervention and had increased cessa-
tion rates and 75% kept current practice cessation
Table 1 Percentage of  smokers that used the smoking cessation interventions as a percentage of  the total number of  smokers in
The Netherlands in 2000 (4.5 million) [44]
Intervention
Percentage of  smokers
using the intervention Data to estimate the percentage of  smokers using the intervention
TC 0.026 In 2001, 1.2 thousand smokers were reached by telephone counseling at STIVORO [28]
MC 0.36 30% of  the GPs provided minimal GP counseling [63]
76% of  the Dutch population contacted their GP at least once a year [44]
 The average number of  contacts for minimal GP counseling was estimated at 0.75 per
week per GP, of  which roughly 71% was a first consultation [64]
35% of  the GPs provided minimal counseling without advice to use NRT [64]
MC + NRT 0.66 65% of  the GPs often to always advised to use NRT in combination with minimal counseling [64]
IC + NRT 0.16 27% of  the lung physicians provided intensive counseling [65]
The average number of  contacts for counseling by a lung physician was estimated at 3.1 per week
per physician [65]
52% of  the lung physicians often to always advised to use NRT in combination with intensive
counseling [65]
IC + Bupr 0.14 48% of  the lung physicians often to always advised to use bupropion in combination with intensive
counseling [65]
IC + Bupr, intensive counseling combined with bupropion; IC + NRT, intensive counseling combined with nicotine patches or gum; MC, minimal GP counseling;
MC + NRT, minimal GP counseling combined with nicotine patches or gum; TC, telephone counseling.
Table 2 Twelve months continuous abstinence rates for current practice and for the different smoking cessation interventions
with 95% confidence intervals for the sensitivity analyses
Intervention
Abstinence
rate (%) 95% CI*
Ratio of  intervention 
abstinence rate to CP
abstinence rate Source
CP 3.4 STIVORO data and three Dutch cohort
studies [28,31–37]
TC 7.6 6.9–8.3 2.2 9 international RCTs [6,38] and 1 Dutch
evaluation study [25]
MC 7.9† 4.7–11.1 2.3 1 Dutch randomized controlled trial [24]
MC + NRT 12.7 11.9–13.5 3.7 17 international RCTs [5,38]
IC + NRT 15.1 14.1–16.1 4.4 26 international RCTs [5,38]
IC + Bupr 17.2 14.0–20.4 5.1 4 international RCTs [4,38]
*For the sensitivity analyses.
†Cessation rate in trial: 8.2%. 9% used minimal GP counseling in combination with nicotine gum; cessation rate for minimal GP counseling only: 8.2 - (0.09 ¥ 11.0) /
0.91 = 7.9%.
CP, current practice; IC + Bupr, intensive counseling combined with bupropion; IC + NRT, intensive counseling combined with nicotine patches or gum; MC, minimal
GP counseling; MC + NRT, minimal GP counseling combined with nicotine patches or gum; TC, telephone counseling.
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rates. This percentage was kept constant at 25% of
smokers in each year during the implementation
period. After the implementation period the cessa-
tion rates returned to current practice levels. Start
and restart rates in the intervention scenarios were
equal to current practice start and restart rates.
Intervention Costs
We have calculated direct health-care costs from a
societal perspective, indicating that these direct cost
estimates were based on estimates of real resource
use. We have not included productivity costs. All
costs were expressed in euros, for the start year
2000. Table 3 presents the calculated costs of the
different smoking cessation interventions. For cur-
rent practice, resource use was based on Dutch
empirical data [24,26–28,39,40]. For the interven-
tion scenarios, resource use was based on practice
guidelines, and, for the duration of pharmaceutical
therapies, on the original international trials under-
lying the effectiveness data. Thus, the costs of an
“optimal” implementation of the smoking cessation
interventions consistent with the effectiveness fig-
ures were estimated. For the unit costs of minimal
GP counseling, we used the standard cost of a GP
consultation from the Dutch manual for costing in
economic evaluations [41]. This standard cost
included overhead and costs of assistants. We
assumed that one GP consultation lasts 10 minutes
and calculated costs per minute. Material costs for
self-help manuals were added separately [24,26].
For the pharmaceutical costs in the intervention sce-
narios, we used average costs per defined daily dose
(DDD) based on data from the Dutch Foundation
for Pharmaceutical Statistics [39]. Costs of adverse
effects were assumed to be negligible [42]. For
Table 3 Cost per smoker of  the components of  smoking cessation interventions for the current practice scenario and for the
intervention scenarios (euros, year 2000 price level)
Intervention Current practice scenario
Volume Unit price Total cost per quit attempt
TC Counselor time (min) 60 0.58* 35
MC GP time (min) 6.5 1.70 11
Self-help manuals 1 1 1
Total 12
MC + NRT GP time (min) 6.5 1.70* 11
Self-help manuals 1 1 1
Prescriptions NRT 1.6 20 32
Total 44
IC + NRT Chest physician time (min) 2 3.3* 7
Lung nurse time (min) 110 1.9* 204
Prescriptions NRT 1.6 20 32
Total 243
IC + Bupr Chest physician time (min) 2 3.3 7
Lung nurse time (min) 110 1.9 204
Prescriptions Bupr 1.5 47 71
Total 282
Intervention Increased intervention scenarios
Volume (min–max)† Unit price Total cost per quit attempt
TC Counselor time (min) 120 (90–150) 0.58 70
MC GP time (min) 12 (3–12) 1.70 20
Self-help manuals 1 1 1
Total 21
MC + NRT GP time (min) 12 (3–12) 1.70 20
Self-help manuals 1 1 1
DDDs NRT‡ 65 (49–141) 2.18§ 142
Total 163
IC + NRT Chest physician time (min) 2 3.3 7
Lung nurse time (min) 90 (40–110) 1.9 167
DDDs NRT‡ 80 (70–93) 2.18§ 175
Total 349
IC + Bupr Chest physician time (min) 2 3.3 7
Lung nurse time (min) 90 (40–110) 1.9 167
DDDs Bupr¶ 63 (49–84) 2.53§ 160
Total 334
*Including overhead.
†For the sensitivity analyses.
‡One DDD equals 14 mg for patches; one DDD equals 30 mg for gum.
§Total price, including a mark-up of  5.67€ to cover pharmacist fees.
¶One DDD equals 300 mg for bupropion.
IC + Bupr, intensive counseling combined with bupropion; IC + NRT, intensive counseling combined with nicotine patches or gum; MC, minimal GP counseling;
MC + NRT, minimal GP counseling combined with nicotine patches or gum; min, minutes; TC, telephone counseling.
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intensive counseling and telephone counseling, the
salary of a counselor (respiratory nurse, or trained
telephone counselor, respectively) per unit of time
was used. The salary costs included material costs
and overhead [28]. In addition, the standard costs
of a lung physician consultation [41] were used to
find the costs of a 2-minute stop advice. Material
costs for self-help manuals were added separately
[27]. Minimum and maximum estimates of resource
use were used in the sensitivity analyses.
In current practice, the estimated intervention
costs per quit attempt were 12€ for minimal GP
counseling, 44€ for minimal GP counseling with
NRT, 243€ for intensive counseling with NRT, 282€
for intensive counseling with bupropion, and 35€
for telephone counseling. For the intervention sce-
narios, the intervention costs were estimated to be
21€, 163€, 349€, 334€, and 70€, respectively.
For each of the five interventions, intervention
costs in the current practice scenario were calcu-
lated as the number of smokers times the propor-
tion currently using the intervention times the
current practice costs per quit attempt. For exam-
ple, for MC in the year 2000 this is 4.5 million times
0.36% times 12€. Intervention costs in the interven-
tion scenarios were calculated as the number of
smokers times the 25% of smokers that get the
intervention times the costs per quit attempt of an
“optimal” use of the intervention. For example, for
MC in the year 2000 this is 4.5 million times 25%
times 21€. The difference between those two calcu-
lations was the additional intervention costs. Costs
of other interventions than the five that were stud-
ied were assumed to remain unchanged.
Model and Input Data
We simulated changes in smoking prevalence rates
and the resulting changes in incidence rates of
smoking-related chronic diseases, using the Chronic
Disease Model [43] that was developed at the
National Institute of Public Health and the Environ-
ment (RIVM) in Bilthoven, The Netherlands. This
dynamic multistate life table model describes the life
course of parallel Dutch population cohorts annu-
ally over time. The model basically consists of a
demographic module that is linked to several dis-
ease-specific modules. In contrast with models that
follow a cohort of people over time and report the
impact of a one-time application of a smoking ces-
sation intervention on morbidity and mortality, the
Chronic Disease Model is a dynamic population
model. It models yearly changes from aging, birth,
migration and mortality based on data from Statis-
tics Netherlands [44]. The prevalence of smoking is
not stable either, because the transitions between
the three smoking classes of never, current, and
former smokers are modeled annually. The net
annual cessation rate depends on the changing mix,
influenced by interventions and by demographic
trends. The disease-specific modules are epidemio-
logical models of risk factor-specific incidence,
prevalence, and mortality of several chronic dis-
eases. When estimating mortality, the model takes
account of competing death risks, combining the
results from the various disease-specific modules
with the demographic module. The model has
Markov properties. This means that, conditional on
sex, age, and risk factor class (never, current, and
former smoker), the health states 1 year ahead are
independent of the past health states. This implies,
for example, that the probability to quit smoking
does not depend on the duration of smoking, i.e.,
within an age and sex group, people have the same
probability to quit smoking. The model is further
based on the assumption of conditional independ-
ence, i.e., conditional on the risk factor class,
disease incidence and mortality rates are assumed to
be mutually independent. This implies, for example,
that given age and sex, the probability for a smok-
ing chronic obstructive pulmonary disease (COPD)
patient to get lung cancer is the same as the pro-
bability for a smoking person without COPD. Nev-
ertheless, because there are more smokers and
former smokers among COPD patients than among
non-COPD patients, an average COPD patient has
a higher risk of getting lung cancer and, conse-
quently, a higher risk of dying of it. The model was
described in more detail elsewhere [43,45,46] and
has previously been used to evaluate the effects of
hypothetical smoking cessation scenarios [47–50].
Reference [47] contains an online appendix with
mathematical details on the model. The current
article is the first time the model is used to assess
the cost-effectiveness of smoking cessation
interventions.
We simulated the effects of increased smoking
cessation rates on changes in smoking prevalence
and the resulting changes in incidence, prevalence,
mortality, and costs of 11 smoking-related diseases,
i.e., coronary heart disease (myocardial infarction
and other coronary heart disease), stroke, COPD,
lung cancer, larynx cancer, oral cavity cancer,
esophagus cancer, pancreas cancer, bladder cancer,
and kidney cancer. We chose 2000 as the start year
of the simulations; Table 4 summarizes the input
data for the 11 smoking-related diseases. This com-
prises data on the incidence, prevalence, and mor-
tality rates of the diseases [45,46], risk ratios for
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incidence for current and former smokers, and qual-
ity of life weights for life-years with these diseases
[51,52]. For example, one life-year with lung cancer
is equal to 0.57 QALY. Conditional on smoking sta-
tus, the model calculated the risk of having two
smoking-related diseases. To do so, it multiplied
age-, sex-, and smoking class-specific prevalence
rates. It was further assumed that the quality-of-life
weight for a combination of diseases was equal to
the worst quality-of-life weight of one of these dis-
eases. Health-care costs for these diseases were
obtained from a Dutch cost-of-illness study that
allocated  total  direct  costs  of  health  care  using
a top-down approach [53]. These 11 diseases
accounted for 9% of the total costs of health care in
The Netherlands in 1999.
Cost-Effectiveness
The additional intervention costs of the intervention
scenarios were calculated as the difference in inter-
vention costs between these scenarios and current
practice. To calculate net costs, the savings from
avoided smoking-related diseases were subtracted
from the additional intervention costs. These net
costs were divided by the gain in life-years or
QALYs to find the costs per life-year or QALY
gained. Future costs and effects were discounted at
the Dutch standard annual percentage of 4% [54].
The time horizon was 75 years.
Sensitivity Analysis
A series of one-way sensitivity analyses was carried
out to investigate the robustness of the cost-effec-
tiveness ratios with regard to variations in cessation
rates, intervention costs, discount rates, time hori-
zon, and the percentage of smokers reached by the
intervention. Cessation rates were varied by their
95%-confidence limits (see Table 2). Intervention
costs were varied from minimum to maximum esti-
mates of resource use (see Table 3). Discount rates
on costs and effects of 0%, 3%, and 5% were used,
and a discount rate of 4% for costs combined with
0% for effects. The percentage of smokers that was
offered the intervention was varied, from 10% to
50% of all smokers. Finally, results were computed
for time horizons of 20, 30, and 50 years.
Results
For each intervention applied to a population of
1000 smokers, Table 5 presents the total number of
extra quitters, additional intervention costs as well
as costs per quitter, compared with the 34 quitters
that would be obtained in current practice. Costs
per quitter ranged from about 450€ for minimal GP
counseling to about 3000€ for intensive counseling
with nicotine patches or gum.
Table 6 shows the model estimates of health
effects and health-care costs for the Dutch popula-
tion when the smoking cessation interventions
were offered for a period of 1, 10, and 75 years.
The table presents in the first two columns cumula-
tive discounted health effects, first the extra life-
years gained from a reduced mortality and second
the extra QALYs gained. The third column gives
the net present value of intervention costs. Com-
bining these, the fourth and the fifth column
present intervention costs per life-year and QALY
gained, respectively. The sixth column then gives
the savings in health-care costs from a reduced
prevalence of smoking related diseases. Finally, the
last two columns present the cost-effectiveness
ratios in terms of costs per life-year or QALY
gained.
Table 4 Incidence rates, risk ratios for incidence for current and former smokers and quality-of-life weights of  11 smoking-related
diseases, stratified by sex
Disease
Incidence rates
(per 1000) [45,46]
Risk ratios for incidence for current and former 
smokers* [52] Quality-of-life
weights [51,52]Current smokers Former smokers
Women Men Women Men Women Men Women Men
Acute myocardial infarction 1.7 3.2 3.2 2.9 1.3 1.6 0.71 0.71
Coronary heart disease 2.2 3.1 3.2 2.9 1.3 1.6 0.71 0.71
Stroke 2.3 2.0 3.8 3.3 1.4 1.3 0.39 0.39
COPD 1.4 2.4 11.8 13.1 7.9 10.7 0.69 0.69
Lung cancer 0.23 1.0 14.2 26.8 4.5 10.6 0.57 0.57
Larynx cancer 0.014 0.083 17.8 10.5 11.9 5.2 0.88 0.88
Oral cavity cancer 0.058 0.12 5.6 27.5 2.9 8.8 0.88 0.88
Esophagus cancer 0.042 0.091 10.3 7.6 3.2 5.8 0.27 0.27
Pancreas cancer 0.088 0.092 2.3 2.1 1.8 1.1 0.44 0.49
Bladder cancer 0.065 0.22 1.9 2.9 1.9 2.6 0.89 0.91
Kidney cancer 0.078 0.11 2.0 3.0 1.9 2.1 0.62 0.76
*Never smokers are reference (risk ratios equal 1).
Feenstra et al.184
Minimal GP counseling was a dominant strategy
compared with current practice, regardless of the
implementation period. For minimal GP counseling
about 330,000 life-years or 410,000 QALYs were
gained with a 75 years implementation period.
About 1.4€ billion in health-care costs for smoking-
related diseases were saved and these savings were
higher than the intervention costs of about 520€
million. The four other interventions yielded higher
costs than savings and cost-effectiveness ratios that
ranged from 1100€ per QALY for telephone coun-
seling to 4900€ for intensive counseling with NRT.
For a 75-year implementation period, the absolute
gain in life-years and QALYs and the savings in
costs for not having to treat smoking-related dis-
eases were highest, but the intervention costs were
also highest. The 1- and 10-year intervention sce-
narios showed lower total intervention costs as well
as lower savings, gains in life-years, and QALYs
than permanent implementation. The cost-effective-
ness ratios were not very much affected by the dura-
tion of the implementation period.
Effects and Costs over Time
The current practice scenario projected a decline in
smoking. The percentage of smokers in the Dutch
population aged 10 years and older decreased from
32% in 2000 to 25% in 2075. Smoking prevalence
increased in older women, but decreased in men of
Table 5 Number of  additional quitters, total additional intervention costs, and costs per quitter for the intervention scenarios
compared with the current practice scenario for a group of  1000 smokers (euros, year 2000 price level)
Intervention Additional quitters*
Additional intervention costs†
(¥1000) Costs per quitter
TC 42 69 1640
MC 45 20 450
MC + NRT 93 162 1750
IC + NRT 117 348 2970
IC + Bupr 138 333 2410
*Compared with 34 quitters for the current practice scenario.
†Compared with intervention costs of  1130€ for the current practice scenario.
IC + Bupr, intensive counseling combined with bupropion; IC + NRT, intensive counseling combined with nicotine patches or gum; MC, minimal GP counseling;
MC + NRT, minimal GP counseling combined with nicotine patches or gum; TC, telephone counseling.
Table 6 Number of  life-years and QALYs gained, total additional intervention costs, intervention costs per LY and QALY gained,
total savings in costs of  care and cost-effectiveness: costs per life-years gained and costs per QALY gained for the different scenarios
cumulative for three different time periods, discounted at 4% for both costs and effects (euros, year 2000 price level)
Intervention
LYs
gained*
(¥104)
QALYs
gained†
(¥104)
Intervention
costs‡ 
(¥109)
Intervention
costs per LY
gained
Intervention
costs per 
QALY
gained
Savings of
treatment
for diseases§
(¥109)
Costs
per LY
gained
Costs
per
QALY
gained
1-year implementation
TC 1.2 1.6 0.077 6,200 4800 0.053 2000 1500
MC 1.4 1.7 0.023 1,700 1300 0.057 ¶ ¶
MC+NRT 2.8 3.6 0.18 6,500 5000 0.12 2300 1700
IC+NRT 3.5 4.5 0.39 11,000 8500 0.15 6800 5200
IC+Bupr 4.1 5.3 0.37 8,900 6900 0.17 4700 3600
10-year implementation
TC 11 14 0.64 5,800 4500 0.46 1600 1200
MC 12 15 0.19 1,600 1300 0.50 ¶ ¶
MC + NRT 23 30 1.4 6,200 4800 0.98 1900 1500
IC + NRT 29 37 3.0 10,500 8100 1.2 6300 4900
IC + Bupr. 33 43 2.8 8,600 6600 1.4 4400 3400
Permanent implementation
TC 31 38 1.7 5,700 4600 1.3 1400 1100
MC 33 41 0.52 1,600 1300 1.4 ¶ ¶
MC + NRT 62 78 3.8 6,100 4800 2.7 1800 1400
IC + NRT 74 94 7.8 10,500 8300 3.2 6200 4900
IC + Bupr 84 110 7.3 8,600 6800 3.6 4300 3400
*Compared with a cumulative total of  412 ¥ 106 life-years from the current practice scenario.
†Compared with a cumulative total of  392 ¥ 106 QALYs from the current practice scenario.
‡Compared with cumulative costs of  continued current practice of  120€ ¥ 106.
§Compared with cumulative costs of  care of  142€ ¥ 109 from the current practice scenario.
¶Minimal GP counseling dominated current practice, due to savings and higher effects.
IC + Bupr, intensive counseling combined with bupropion; IC + NRT, intensive counseling combined with nicotine patches or gum; LYs, life-years; MC, minimal GP coun-
seling; MC + NRT, minimal GP counseling combined with nicotine patches or gum; QALYs, quality-adjusted life-years; TC, telephone counseling.
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all ages and in young women. For the youngest age
groups of both men and women, the decline was
quite small. For the intervention scenarios reaching
25% of the smokers, the percentage of smokers
declined to 21% in 2075 for permanent implemen-
tation of intensive counseling with bupropion at
maximum. For the intervention scenarios of 1- and
10-year implementation periods, effects on the
number of smokers gradually disappeared after the
intervention stopped because of relapse and new
young smokers, and the percentage of smokers in
2075 was 25%, the same as in the current practice
scenario. In all scenarios, a lag time between an
increased implementation of smoking cessation
interventions and the full gain in life-years and
QALYs could be observed. After implementation,
first the number of quitters increases, decreasing the
number of smokers and increasing the number of
former smokers. This leads to a reduced incidence
of smoking-related diseases and hence a reduced
prevalence. In turn, that causes a reduced mortality.
Reduced mortality is counted as life-years gained.
The combined reduction in prevalence and mortal-
ity gives the QALY gain. For 1- and 10-year imple-
mentation periods, reductions in mortality reach a
top, about 15 and 20 years after implementation,
respectively, then the gain compared with current
practice declines again, to nearly zero, about
65 years after implementation, so that the full gain
is obtained within the model’s time horizon.
Sensitivity Analysis
Figure 1 depicts the uncertainty in resource use and
effectiveness. It presents gains in total costs, includ-
ing savings from reductions in the incidence of 11
smoking-related diseases, and QALYs plus uncer-
tainty ranges over resource use and cessation rates,
for permanent (i.e., 75 years) implementation of the
smoking cessation interventions compared with
current practice. Changes in cessation rates led not
only to changes in QALYs gained but also to
changes in the incidence of smoking-related dis-
eases and hence to changes in total additional costs.
This explains why the horizontal confidence lines
in Figure 1 were not completely horizontal, but
slightly diagonal. The relatively large uncertainty
about the effectiveness of minimal GP counseling
was reflected by the relatively wide horizontal
uncertainty range. Nevertheless, the result that min-
imal GP counseling is a cost-saving intervention was
robust for uncertainties in resource use and effects.
The figure shows that uncertainty ranges over-
lapped, so that the dominance of intensive coun-
seling with bupropion over intensive counseling
with NRT was quite uncertain, while that of mini-
mal GP counseling over telephone counseling was
also uncertain. Besides, because of the large uncer-
tainty range in costs, it might well be that minimal
counseling with NRT was also dominated by either
intensive counseling with NRT or intensive coun-
seling with bupropion. Cost-effectiveness ratios
became more favorable when the time horizon
increased, so that more of the gains were included.
Minimal GP counseling was dominant for all time
horizons considered. For intensive counseling with
bupropion, costs per QALY gained ranged from
about 13,000€ for a time horizon of 20 years to
3900€ for a time horizon of 50 years, compared
with 3400€ for a time horizon of 75 years. Cost-
effectiveness ratios were not sensitive to changes in
the percentage of smokers that was offered the
intervention, which ranged from 10% to 50% of all
smokers. Table 7 shows incremental cost-effective-
ness ratios for different discount rates for costs and
effects, compared with current practice, for 75-year
intervention scenarios. Discounting clearly affected
Figure 1 Total additional costs and total
quality-adjusted  life-years  (QALYs)  gained
for the intervention scenarios compared with
current practice with the range in costs and
effects based on the sensitivity analyses,
cumulative for the years 2000–2075. TC,
telephone counseling; MC, minimal GP
counseling; MC + NRT, minimal GP coun-
seling combined with nicotine patches or
gum; IC + NRT, intensive counseling com-
bined with nicotine patches or gum;
IC + Bupr, intensive counseling combined
with bupropion.
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the cost-effectiveness ratios, reducing the impact of
both future savings in health-care costs and future
health effects. To illustrate the effect of discounting,
a life-year gained 75 years from now weights for
full if health effects are not discounted, while it
weights for 0.11, 0.053, or 0.026 if health effects
are discounted at 3%, 4%, or 5%, respectively.
Because health effects occur with a delay, while
intervention costs start immediately, the effect of
higher discount rates will be that the net present val-
ues of health effects, and related savings in health-
care costs decrease, while the net present value of
intervention costs decreases much less. As a result,
cost-effectiveness ratios become worse as the dis-
count rate increases.
Discussion and Conclusions
In conclusion, when assessing the cost-effectiveness
of five face-to-face smoking cessation interventions,
we found that minimal GP counseling was cost-
saving compared with current practice, whereas the
cost-effectiveness ratios of minimal counseling plus
nicotine replacement therapy, intensive counseling
with nicotine replacement therapy, intensive coun-
seling with bupropion, and telephone counseling
were quite small. Implementation of these interven-
tions on a permanent basis for 25% of all smokers
resulted in estimated cost-effectiveness ratios that
ranged from 1400€ per life-year or 1100€ per
QALY gained for telephone counseling to 6200€ per
life-year or 4900€ per QALY gained for intensive
counseling in combination with NRT.
The cost-effectiveness ratios were sensitive to the
rate of discount, the time horizon, resource use
estimates, and cessation rates. Nevertheless, the
cost-effectiveness ratios remained rather low for the
variations in the discount rate, time horizon, cessa-
tion rates, and resource use that were analyzed in
the sensitivity analyses. The ratios did not vary
much with the percentage of smokers reached or the
length of the implementation period.
For several reasons the ratios above were
conservative estimates of the cost-effectiveness. The
effects of smoking cessation on the course of dis-
eases were not included, nor were the effects of pas-
sive smoking and the effects of smoking cessation
by pregnant women on the health of their future
infants.
Furthermore, savings from reduced productivity
losses were not included. Finally, it should be noted
that a large part of the future effects of the inter-
vention efforts during the last 15 to 20 years of the
permanent implementation scenario were not taken
into account, because these health gains occurred
outside the model’s time horizon of 75 years. For
the 1- and 10-year implementation scenarios, all
health gains occurred within the time horizon, and
this bias was avoided.
In contrast, three reasons why our results may
overestimate cost-effectiveness ratios must be men-
tioned. First, the estimates of effectiveness were
obtained from clinical trials. If trial populations were
a selection of motivated smokers, our cessation rates
would be too high. This applies in particular to the
more intensive interventions but less to minimal GP
counseling with, or without NRT, and telephone
counseling, because for the latter interventions, trials
were often done in an unselected group of smoking
GP patients. The second is that the model did not
include a delay effect of smoking cessation, i.e., all
quitters received the lower relative risks of disease
incidence of former smokers the year after quitting.
However, the estimates of the relative risks in our
model were conservative. Relative risks of former
smokers were estimated as an average of the relative
risks of all former smokers regardless of how long
ago they had stopped. This implies that for the first
years after quitting the reduction in relative risk in
our model was too high, while for later years it was
Table 7 Incremental costs per QALY gained for the intervention scenarios for different discount rates for both costs and effects,
cumulative for the time period 2000–2075 (euros, year 2000 price level)
Intervention
Costs per QALY for different discount rates
Discount rate
for costs and effects 3%
Discount rate for costs
and effects 5%
Discount rate for costs 4%
and for effects 0%
Discount rate for costs
and effects 0%
TC 720 1600  240  10
MC * * * *
MC + NRT 990 2000  310  210
IC + NRT 4000 5900 1,000 2,300
IC + Bupr 2700 4200  730 1,400
*Minimal GP counseling dominated current practice, due to savings and higher effects.
IC + Bupr, intensive counseling combined with bupropion; IC + NRT, intensive counseling combined with nicotine patches or gum; MC, minimal GP counseling;
MC + NRT, minimal GP counseling combined with nicotine patches or gum; QALY, quality-adjusted life-year; TC, telephone counseling.
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too low. Third, in contrast with most cost-effective-
ness analyses of smoking cessation, we took savings
of avoided smoking-related diseases into account.
Health-care costs unrelated to smoking in life-years
gained from smoking cessation, for instance, costs of
care for dementia, were ignored in our computa-
tions. Whether or not costs of care for diseases not
related to smoking (so-called unrelated medical
costs) that occur during added years of life should be
included in cost-effectiveness analyses is a topic of
discussion in the literature [55–57]. The current con-
vention in economic evaluation is to ignore unrelated
medical costs. Indeed, textbooks and guidelines
[54,55] recommend the exclusion of medical costs
during  life-years  gained,  unless  there  is  a causal
relationship between the intervention and these
costs. It was recently argued that it is theoretically
more sound to include the survivor costs (i.e., general
costs of care that occur during the added years of life)
if they present resources that directly produce the
utility that is being measured in the denominator of
the cost-effectiveness ratio [56]. In practice, most
cost-effectiveness analyses exclude unrelated costs
of care, partly for reasons of data availability. Given
current guidelines and to enable comparison with
other cost-effectiveness analyses, in the present study
these unrelated medical costs were also excluded.
To  have  very  conservative  estimates  of  the
cost-effectiveness ratios, we also computed the
ratio of intervention  costs  to  the  difference  in
QALYs  or  life-years,  and presented them in
Table 6. Intervention costs per life-year gained var-
ied from about 1,600€ for minimal GP counseling
to 10,500€ for intensive counseling combined with
NRT for 75-year implementation periods.
Our study differs from other cost-effectiveness
analyses of smoking cessation, because we used a
dynamic population model. We did not model a
closed cohort of smokers until their death, as most
studies do [14,16,19,23,58], but estimated effects
for the Dutch population. The model included
relapse after 12 months continuous abstinence and
inflow of new young smokers. Not all smokers who
quit in the 1-year scenario would remain nonsmok-
ers for the whole time horizon. This led to higher
cost-effectiveness ratios than would be obtained if
restart rates were ignored. In addition, the model
takes  account  of  the  demographic  changes  in
the population and the changes in incidence and
prevalence of the risk factor of smoking and the
smoking-related diseases.
Furthermore, we could model 10- and 75-year
implementation periods and compare these to a 1-
year implementation. Our finding that the imple-
mentation period did not much affect the cost-
effectiveness  ratios  was  partly  influenced  by  the
simplifications that had to be made to keep the
model tractable and use reliable input data. Cessa-
tion rates were assumed constant over time, and
smokers, as well as former smokers, were modeled
as homogeneous groups with average age- and sex-
specific cessation rates and restart rates, respec-
tively, ignoring smokers’ individual quit and relapse
history. If cessation and restart rates would depend
on the number of previous quit attempts, this would
influence the outcomes in longer implementation
periods. Inclusion of this, however, would strongly
complicate the model, while reliable input data
were not available.
Despite the methodological differences, our cost-
effectiveness ratios were within the range of values
found in the literature. Converting all outcomes
into Dutch currency for the year 2000, values in the
literature varied from 200€ to 10,000€ per life-year
gained [8,9,12–23]. Our result that costs per life-
year gained of intensive counseling with bupropion
were more favorable than those of intensive coun-
seling with NRT was in line with former research
[7,9,11].
Comparing the results for the five interventions
to each other, two interventions were relatively
cheap: minimal GP counseling and telephone coun-
seling. But they were also less effective than the
other interventions. The effectiveness of minimal
GP counseling was based on a single Dutch trial
[24]. This was reflected by the large uncertainty
range. We choose this trial instead of a Cochrane
meta-analysis on physician counseling [59], because
we felt that the 11 studies on minimal counseling
included in the meta-analysis did not sufficiently
reflect the Dutch minimal GP counseling. The find-
ing that minimal GP counseling is cost-saving, how-
ever, was robust. Two other interventions, intensive
counseling combined with either NRT or bupropion
were more expensive, but they were also more effec-
tive. Although their cost-effectiveness ratios were
higher than the ratios of minimal GP counseling and
telephone counseling, they remained low. For these
interventions, costs were more difficult to estimate,
because of variations in the duration and intensity
of counseling and the duration of NRT use. The
costs of one intervention, minimal GP counseling
combined with NRT, fell in between. However, its
costs were highly uncertain, resulting in an uncer-
tainty range that goes from slight cost savings up to
high additional costs. This was in line with results
from the Cochrane meta-analysis [5] that stated
that the added effect of NRT to low intensity coun-
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seling was hard to prove. The trials included in this
meta-analysis showed a high variance in the dura-
tion of NRT, mainly because of differences in
compliance.
The cost-effectiveness ratios, even for the most
resource intensive cessation interventions were well
below many other commonly recommended medi-
cal and surgical interventions. This highlights the
cost-effectiveness of smoking cessation interven-
tions, which affects many smoking-related diseases.
How favorable the cost-effectiveness ratios are
can be demonstrated by comparing them with other
preventive interventions. For example, the Dutch
1998 cholesterol guidelines advise to reimburse
cholesterol-lowering therapy up to approximately
20,000€ per QALY [60,61]. The cost-effectiveness
of smoking cessation is roughly within the same
range as the cost-effectiveness of breast cancer
screening in The Netherlands (4000€ per life-year
gained) and the cost-effectiveness of the Dutch
influenza vaccination program for the elderly
(1800€ per life-year gained) [62].
The  work  described  above  was  conducted  to  support
the Dutch Public–Private Partnership to reduce tobacco
dependence, in developing Dutch smoking cessation
guidelines for health-care professionals. The following
persons are thanked for their helpful comments on earlier
drafts: P. Anderson, R.M. Baltussen, W. Bemelmans, J.
van der Laan, L. Niessen, M.E. Pieterse, J. Polder, E.J.
Wagena, C. van Weel, R. Welte, and G.A. de Wit.
Sources of financial support: Dutch Public–Private Part-
nership to reduce tobacco dependence.
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